Alzamend Neuro (ALZN) to Post Earnings on Wednesday

Alzamend Neuro (NASDAQ:ALZN) is expected to release its Q1 2027 results before the market opens on Wednesday, September 9th. Analysts expect the company to post earnings of ($0.56) per share for the quarter. Interested persons can check the company’s upcoming Q1 2027 earning summary page for the latest details on the call scheduled for Wednesday, September 16, 2026 at 8:00 AM ET.

Alzamend Neuro (NASDAQ:ALZN) last announced its earnings results on Wednesday, July 22nd. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.07). On average, analysts expect Alzamend Neuro to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Alzamend Neuro Stock Performance

Shares of ALZN stock opened at $1.66 on Tuesday. The firm has a market capitalization of $8.02 million, a price-to-earnings ratio of -0.57 and a beta of 0.23. Alzamend Neuro has a fifty-two week low of $0.84 and a fifty-two week high of $2.68. The stock’s 50-day simple moving average is $1.40 and its 200-day simple moving average is $1.37.

Analyst Ratings Changes

Separately, Weiss Ratings raised shares of Alzamend Neuro from a “sell (e)” rating to a “sell (e+)” rating in a report on Monday, August 31st. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $28.00.

Institutional Investors Weigh In On Alzamend Neuro

An institutional investor recently raised its stake in Alzamend Neuro stock. DRW Securities LLC lifted its holdings in Alzamend Neuro, Inc. (NASDAQ:ALZN) by 27.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 116,319 shares of the company’s stock after purchasing an additional 25,074 shares during the period. DRW Securities LLC owned about 3.06% of Alzamend Neuro worth $212,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 49.61% of the company’s stock.

About Alzamend Neuro

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.